Remdesivir of scant benefit in hospitalized COVID patients, study finds | CIDRAP

The antiviral drug remdesivir had little effect in patients with moderate COVID-19 in 105 hospitals in the United States, Europe, and Asia in a randomized, controlled, open-label trial published late last week in JAMA, adding to a mixed picture of the drug in randomized clinical trials (RCTs), which are considered the gold standard for gauging interventions.

Source: Remdesivir of scant benefit in hospitalized COVID patients, study finds | CIDRAP